2005
A NOVEL AGE CROSSLINK EXHIBITING IMMUNOLOGICAL CROSS-REACTIVITY WITH AGES FORMED IN VIVO
Al-Abed Y, Bucala R. A NOVEL AGE CROSSLINK EXHIBITING IMMUNOLOGICAL CROSS-REACTIVITY WITH AGES FORMED IN VIVO. 2005, 239-244. DOI: 10.1533/9781845698447.7.239.Peer-Reviewed Original Research
2000
Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine 2000, 6: 114-125. PMID: 10859028, PMCID: PMC1949938, DOI: 10.1007/bf03401779.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesCattleChromatography, AffinityCross ReactionsDiabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycation End Products, AdvancedGlyceraldehydeGlyoxalHumansImmunoblottingKidney Failure, ChronicLysineMaillard ReactionOxidation-ReductionPyruvaldehydeRabbitsRenal DialysisConceptsAGE antibodyCML-AGEDiabetic patientsAGE-bovine serum albuminShort Chain SugarsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsAutoxidation of sugarsImmunization of rabbitsCML-BSADiabetic serumSerum albuminAdvanced glycationAGE contentSugar autoxidationRabbit serum albuminAGE modificationAntibodiesImmunological evidenceApparent molecular weightPatientsAge 3AgeImmunoblot analysis
1999
Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †
Al-Abed Y, Bucala R. Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †. Bioconjugate Chemistry 1999, 11: 39-45. PMID: 10639083, DOI: 10.1021/bc990061q.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsLow-density lipoproteinAGE-modified formCertain diabetic complicationsClasses of antibodiesBeta-amyloid peptideDiabetic complicationsPathological sequelaePrognostic informationAGE formationAGE adductsImmunoreactive fractionEnd productsInhibition of formationVivo ageAgeAntibodiesLines of evidenceVivoCross-linking adductsGlucoseTissueComplications
1998
Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers
Nicholl I, Stitt A, Moore J, Ritchie A, Archer D, Bucala R. Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers. Molecular Medicine 1998, 4: 594-601. PMID: 9848076, PMCID: PMC2230315, DOI: 10.1007/bf03401759.Peer-Reviewed Original ResearchConceptsNondiabetic smokersTissues of smokersCoronary arteryGlycation endproductsSingle greatest preventable causeGreatest preventable causeEnd-organ complicationsAnti-AGE antibodyConsequence of diabetesAdvanced glycation endproductsRenal insufficiencyCigarette smokersPreventable causeSmokersCigarette smokeHigh levelsCausal associationNonsmokersDiabetesMainstream cigarette smokeBlood vesselsAgeExtracellular matrix proteinsArteryLens fiber cells
1997
Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis
Bucala R. Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis. Trends In Cardiovascular Medicine 1997, 7: 39-47. PMID: 21235862, DOI: 10.1016/s1050-1738(96)00137-5.Peer-Reviewed Original ResearchLow-density lipoproteinDiabetic patientsLDL levelsElevated LDL levelsEnzyme-linked immunosorbent assay (ELISA) techniqueRecent clinical observationsAdvanced glycosylation reactionsImmunosorbent assay (ELISA) techniqueVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallClearance mechanismsNitric oxidePatientsRadical generating systemELISA analysisAgeLipoproteinOxidative modification
1996
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996, 382: 275-278. PMID: 8717046, DOI: 10.1038/382275a0.Peer-Reviewed Original ResearchConceptsAGE crosslinksAdvanced glycation pathwayLow-density lipoproteinPotential therapeutic approachPotential pharmacological strategiesFormation of AGEsReactive α-dicarbonylsPharmacological strategiesGlycation pathwayTherapeutic approachesAdvanced glycationNon-enzymatic glycosylationCollagen crosslinkingNormal agingN-phenacylthiazolium bromideConnective tissueCellular receptorsAgeGlycationTissueProtein crosslinksPost-translational modification processMatrix componentsVivo pointAccelerated rateWhat is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?
Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Research And Clinical Practice 1996, 30: s123-s130. PMID: 8964186, DOI: 10.1016/s0168-8227(96)80048-9.Peer-Reviewed Original ResearchConceptsDiabetic patientsLDL levelsEndothelium-derived relaxing factorsElevated LDL levelsEffects of hyperglycemiaLow-density lipoproteinRelaxing factorsVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallELISA techniqueClearance mechanismsNitric oxideClearance kineticsPatientsELISA analysisLDLAgeAminoguanidineLipoprotein
1994
Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease
Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease. Drug Development Research 1994, 32: 77-89. DOI: 10.1002/ddr.430320204.Peer-Reviewed Original ResearchAdvanced glycosylationVascular diseasePhase II clinical trialOxidized low-density lipoproteinSpecific therapeutic modalitiesLow-density lipoproteinDirect toxic effectReversible Schiff base adductsClinical trialsAdvanced glycosylation endproductsTherapeutic modalitiesVascular permeabilityDensity lipoproteinLipoprotein depositionVascular wallELISA techniqueHeterogenous groupPathological effectsEndothelial cellsPharmacological inhibitorsPathological conditionsAgeToxic effectsLipoproteinDiseaseComparative analysis of DNA mutations in lacI transgenic mice with age
Lee A, Desimone C, Cerami A, Bucala R. Comparative analysis of DNA mutations in lacI transgenic mice with age. The FASEB Journal 1994, 8: 545-550. PMID: 8181674, DOI: 10.1096/fasebj.8.8.8181674.Peer-Reviewed Original Research